Vici Capital

Vici Capital is a healthcare-focused investment and development firm that operates primarily through its subsidiary, Vici Health Sciences. The company specializes in the development of high-value pharmaceutical products, utilizing the FDA's 505(b)(2) regulatory pathway to create improved versions of existing drugs. Vici's core expertise includes formulation development for complex dosage forms such as injectables, ophthalmics, and transdermal systems. The firm targets therapeutic areas with significant unmet needs, including oncology, central nervous system disorders, and rare diseases. By combining internal R&D capabilities with strategic capital, Vici Capital aims to accelerate the commercialization of cost-effective and clinically superior therapies.